Printed from Voxsanity (voxsanity.com.au) — NCT07455071 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Ovarian Cancer Trial, Not Yet Recruiting
NCT07455071
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women between 18 and 70 years old (including those ages) who weigh at least 45 kg.
- People whose cancer did not fully respond to at least one round of standard treatment (surgery and platinum-based chemotherapy), and who still have abnormal CA125 blood levels or at least one area of cancer that can be measured on a scan.
- People whose tumor tissue has already been through genetic and molecular testing, and whose results show they may be suitable for a personalised treatment approach based on their tumour's unique features.
- People whose blood test results meet specific thresholds for white blood cells, lymphocytes, platelets, haemoglobin, liver enzymes, bilirubin, kidney function, and blood clotting (confirm exact values with the trial site).
- People whose heart tracing (ECG) shows no serious irregular heartbeat and a specific heart rhythm measurement (QTcF) of 480 milliseconds or less.
- People whose side effects from previous treatments have largely resolved — generally to a mild level or better — with the exception of stable, mild nerve-related symptoms or hair loss.
- People who have suitable veins for blood collection and are able to have a specific type of immune cell collected from their blood.
- People whose doctors expect them to live for more than 6 months.
- People who are well enough to carry out normal daily activities, or who have only minor limitations, as measured by a standard medical scale (ECOG score of 0 or 1).
- People who are able to become pregnant must agree to use effective contraception throughout the trial and for at least 6 months after the last treatment, and must have a negative pregnancy test within 28 days before joining and again at the start of the trial.
- People who understand what the trial involves, are willing to follow the trial procedures, and have signed the consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a history of strong allergic reactions to two or more different medicines, or who are known to be allergic to any ingredient in the trial's personalised cell therapy (including the cell storage solution CS10, human albumin, or saline).
- People who have been diagnosed with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML), now or in the past.
- People who have cancer that has spread to the brain or the lining around the brain and spinal cord, where symptoms are present and not well controlled.
- People with serious or uncontrolled health conditions, such as uncontrolled heart rhythm problems, a heart attack within the past 3 months, uncontrolled severe seizures, unstable spinal cord compression, blockage of a major vein near the heart (superior vena cava syndrome), immune system deficiency (except due to spleen removal), or other conditions the trial doctor considers high risk.
- People who test positive for HIV, syphilis (TP antibody), or Hepatitis C, or who show signs of active Hepatitis B infection.
- People with moderate to severe heart failure (classified as NYHA Grade III or IV), or significant heart rhythm problems that are not well managed.
- People with high blood pressure that is not controlled (top number 160 mmHg or above, or bottom number 100 mmHg or above).
- People with any of the following health history or current conditions: an autoimmune disease that has required long-term immune-suppressing medication (more than 2 months); immune-related nerve or muscle disease; a history of a severe skin reaction called Toxic Epidermal Necrolysis; a psychiatric condition that would affect the ability to give informed consent or complete the trial; long-term use of certain immune-affecting medications (non-inhaled steroids, hydroxyurea, or immunomodulatory drugs); another active cancer diagnosed within the past 5 years (certain fully cured skin or bladder cancers may be exceptions — confirm with the trial site); or hypothyroidism other than the type managed only with thyroid hormone replacement.
- People whom the trial doctor considers unsuitable for the trial, including those with a persistent fever or an active, uncontrolled infection at the time of screening.
- People who have received certain immune cell therapies (such as CIK, DC, DC-CIK, or LAK cell therapies) within the past 6 months.
- People who received a platelet or red blood cell transfusion within 3 weeks before the scheduled blood cell collection.
- People who received chemotherapy within 3 weeks before the scheduled blood cell collection.
- People who received certain targeted cancer medicines (anti-angiogenic TKI drugs) within 3 weeks before the scheduled blood cell collection.
- People who used steroid medicines or other immune-affecting therapies taken throughout the body within 3 weeks before the scheduled blood cell collection.
- People who participated in another clinical trial involving an experimental non-biological treatment within the past 30 days (or 5 half-lives of that drug, whichever is longer), or an experimental biological treatment such as an antibody therapy within the past 4 months (or 5 half-lives, whichever is longer).
- People who are pregnant or breastfeeding.
- People whose tumour genetic analysis indicates their cancer is unlikely to respond to immunotherapy.
- People whom the trial doctor considers unable to follow the trial procedures, or unsuitable for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Phone: 13701085402
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Peking University Third Hospital
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
30 September 2027
Primary endpoints
Evaluate the safety and tolerability of YS247 in study participants with HRD-negative epithelial ovarian cancer, and to determine the Maximum Tolerated Dose (MTD) / Recommended Expansion Dose.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.